|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Thermal crosslinking of organic semiconducting polythiophene improves transverse hole conductivity显示文摘 | Gearba I R Nam C Y Pindak R | | 0，，17： | 1 |
| 2 | Enterovesical fistulas in Crohn's disease显示文摘 | Pechan J Pindak D Lutter I | | 0，，07： | 1 |
| 3 | The clinical value of the procalcitonin in prediction of severity and outcome in acute pancreatitis显示文摘 | PINDAK D PARRAK V PECHAN J | 2003 | Hepatogastroenterology2003，50，2： | 1 |
| 4 | Structural measurements on the liquid crystal analog of the Abrikosov phase显示文摘 | Srajer G Pindak R Waugh M A | 1990 | Phys Rev Lett1990，64，13： | 1 |
| 5 | Septic complication of acute pancreatitis显示文摘 | Mifkovic A Pindak D Daniel I | 2006 | Brtisl Lek Listy2006，107，8： | 1 |
| 6 | The clinical value of the procalcitonin in prediction of severity and outcome in acute pancreatitis 显示文摘 | Pindak D Parrak V Pechan J | 2003 | Hepatogastroenterology2003，50，2： | 1 |
| 7 | Septic complications of acute pancreatitis 显示文摘 | Mifkovie A Pindak D Daniel I | 2006 | Bratisl Lek Listy2006，107，8： | 1 |
| 8 | The clinical value of the procalcitonin in prediction of severity and outcome in acute pancreatitis显示文摘 | Pindak D Parrak V Pechan J | | 0，，2： | 1 |
| 9 | Growth and cytopathogericity of Trichomonas vaginalis in tissures cultures显示文摘 | Gardner WA Pindak MM | 1986 | Jchin Microbiol1986，23，： | 1 |
| 10 | Septic complications of acute pancreatitis显示文摘 | Mifkovic A Pindak D Daniel L | | 0，，： | 1 |
| 11 | Septic complications of acute pancreatitis 显示文摘 | Mifkovic A Pindak D Daniel I eta/ | 2006 | Bratisl Lek Listy2006，107，8： | 1 |
| 12 | The clinical value of the procalcitonin in prediction of severity and outcome in acute pancreatitis显示文摘 | Pindak D Parrak V Pechan J | 2003 | Hepatogastroenterology2003，50，： | 1 |
| 13 | Septic complications of acute pancreatitis显示文摘 | Mifkovic A Pindak D Daniel I | 2006 | Bratisl Lek Listy2006，107，8： | 1 |
| 14 | Specific aspects of acute pancreatitis显示文摘 | Miflcovic A Skultety J Pindak D | 2009 | Bratisl Lek Listy2009，110，9： | 1 |
| 15 | The clinical value of the procalcitonin in prediction of severity and outcome in acute pancreatitis显示文摘 | Pindak D Parrak V Pechan J | 2003 | Hepatogastroenterology2003，502，： | 1 |
| 16 | Circulating tumor cells and drug history in primary breast cancer patients显示文摘Aim:Different types of chronic medication may affect breast cancer prognosis.Circulating tumor cells(CTCs)play an important role in cancer metastasis formation.There is no evidence of how chronic medication affects CTCs and breast cancer prognosis.The aim of this study was to evaluate association between chronic medication and CTCs in patients with primary breast cancer.Methods:This study involved 414 patients with stage I-III primary breast cancer.Chronic drug history was collected from patients’medical records and included all drugs that were prescribed for patients over at least the last 6 months prior to CTCs evaluation.CTCs were detected using a quantitative real-time polymerase chain reaction(qRT-PCR)-based method at the time of breast surgery.Results:There was no association between CTCs,including their different subpopulations and chronic medication.Chronic medication using angiotensin-converting-enzyme inhibitors(ACEi),metformin,and insulin were associated with inferior disease-free survival(HR=0.49,95%CI 0.26-0.94,P=0.007 for ACEi;HR=0.27,95%CI 0.08-0.91,P<0.001 for metformin;and HR=0.12,95%CI 0.01-2.91,P<0.001 for insulin)and this was most pronounced in patients with epithelial to mesenchymal transition(CTC_EMT)phenotype.In multivariate analysis,chronic administration of metformin and/or insulin was an independent predictor of inferior outcome.Conclusion:Our findings show that there was no association between chronically used medication and CTCs in primary breast cancer patients.However,administration of ACEi,metformin,and/or insulin could negatively affect prognosis of patients with CTC_EMT. | Silvia Jurisova Marián Karaba Gabriel Minarik Juraj Benca Tatiana Sedlackova Daniela Manasova Katarina Kalavska Daniel Pindak Jozef Mardiak Michal Mego | 2020 | Cancer Drug Resistance2020，3，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员